Reneo appoints Paul Hoelscher to board and audit committee chair; two directors exit

OnKure Therapeutics, Inc.

Paul Hoelscher appointed Class I director and Audit Committee Chair, effective Jan 20, 2022.
Hoelscher receives $40k annual cash retainer plus $15k as Audit Committee Chair, and option for 35,000 shares vesting over 3 years.
Lon Cardon will not stand for re-election at 2022 annual meeting due to new role at Jackson Laboratory.
Kenneth Harrison resigned from board effective Jan 20 to focus on other endeavors; no disputes involved.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Paul Hoelscher

Class I Director and Audit Committee Chair

OKUR · OnKure Therapeutics, Inc.

Effective: 2022-01-20
Filed: January 24, 2022, 6:59 PM ET

On January 20, 2022, the Board of Directors (the “Board”) of Reneo Pharmaceuticals, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Paul Hoelscher as (i) a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, (ii) a member of the Audit Committee of the Board (the “Audit Committee”) and (iii) Chair of the Audit Committee

Departed

Kenneth Harrison

Director

OKUR · OnKure Therapeutics, Inc.

Effective: 2022-01-20
Filed: January 24, 2022, 6:59 PM ET

On January 20, 2022, Kenneth Harrison, Ph.D. resigned from the Board to focus on other endeavors.

Departed

Lon Cardon

Class I Director

OKUR · OnKure Therapeutics, Inc.

Filed: January 24, 2022, 6:59 PM ET

On January 18, 2022, Lon Cardon, Ph.D. informed the Company that he will not stand for re-election as a member of the Board when his term as a Class I director expires at the Company’s 2022 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul Hoelscher was appointed as Class I Director and Audit Committee Chair at OnKure Therapeutics, Inc..

Action: appointed
Role: Class I Director and Audit Committee Chair

Exact text from the filing

On January 20, 2022, the Board of Directors (the “Board”) of Reneo Pharmaceuticals, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Paul Hoelscher as (i) a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, (ii) a member of the Audit Committee of the Board (the “Audit Committee”) and (iii) Chair of the Audit Committee

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth Harrison resigned as Director at OnKure Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On January 20, 2022, Kenneth Harrison, Ph.D. resigned from the Board to focus on other endeavors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lon Cardon departed as Class I Director at OnKure Therapeutics, Inc..

Action: will not stand for re-election
Role: Class I Director

Exact text from the filing

On January 18, 2022, Lon Cardon, Ph.D. informed the Company that he will not stand for re-election as a member of the Board when his term as a Class I director expires at the Company’s 2022 annual meeting of stockholders.

View on SEC.gov

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-016015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.